<DOC>
	<DOCNO>NCT02957994</DOCNO>
	<brief_summary>To evaluate various marker renal function bone density switch Tenofovir alafenamide fumarate ( TAF ) chronic hepatitis B patient currently treat Tenofovir disoproxil fumarate ( TDF ) .</brief_summary>
	<brief_title>TAF Switch Study Hepatitis B Monoinfection</brief_title>
	<detailed_description>The investigator previously report prevalence abnormal renal tubular reabsorption phosphate among CHB patient treat 18 month TDF 48 % . Renal tubular dysfunction associate TDF may reversible TDF discontinue 4 . Recently , TAF 25 mg daily show comparable efficacy TDF 300 mg respect viral suppression HBeAg positive HBeAg negative CHB patient ( study 110 108 ) 48 week therapy . As speculated , systemic exposure tenofovir significantly less patient expose TAF compare TDF strikingly less effect note variety renal bone parameter individual receive TAF . Notably , however , question remain improvement may see CHB patient switch TDF TAF . The investigator propose prospective open label study evaluate various marker renal function bone density 80 CHB patient currently treat TDF switch TAF .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Patients chronic hepatitis B ( either HBeAg reactive nonreactive ) Treated TDF unquantifiable Hepatitis B Virus ( HBV ) DNA sensitive Polymerase chain reaction ( PCR ) assay minimum 6 month No prior nucleos ( ) ide exposure prior treatment TDF Treatment TDF minimum 12 month HIV Infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>